Hide metadata

dc.date.accessioned2019-04-04T15:46:28Z
dc.date.available2019-04-04T15:46:28Z
dc.date.created2019-02-12T12:35:36Z
dc.date.issued2019
dc.identifier.citationGanan, Monica Lorentzen, Silje Benedicte Agger, Jane W. Heyward, Catherine A. Bakke, Oddmund Knutsen, Svein Halvor Aam, Berit B. Eijsink, Vincent G. H. Gaustad, Peter Sørlie, Morten . Antifungal activity of well-defined chitooligosaccharide preparations against medically relevant yeasts. PLoS ONE. 2019, 14(1)
dc.identifier.urihttp://hdl.handle.net/10852/67560
dc.description.abstractDue to their antifungal activity, chitosan and its derivatives have potential to be used for treating yeast infections in humans. However, to be considered for use in human medicine, it is necessary to control and know the chemical composition of the compound, which is not always the case for polymeric chitosans. Here, we analyze the antifungal activity of a soluble and well-defined chito-oligosaccharide (CHOS) with an average polymerization degree (DPn) of 32 and fraction of acetylation (FA) of 0.15 (C32) on 52 medically relevant yeast strains. Minimal inhibitory concentrations (MIC) varied widely among yeast species, strains and isolates (from > 5000 to < 9.77 μg mL-1) and inhibition patterns showed a time- and dose-dependencies. The antifungal activity was predominantly fungicidal and was inversely proportional to the pH, being maximal at pH 4.5, the lowest tested pH. Furthermore, antifungal effects of CHOS fractions with varying average molecular weight indicated that those fractions with an intermediate degree of polymerization, i.e. DP 31 and 54, had the strongest inhibitory effects. Confocal imaging showed that C32 adsorbs to the cell surface, with subsequent cell disruption and accumulation of C32 in the cytoplasm. Thus, C32 has potential to be used as a therapy for fungal infections.en_US
dc.languageEN
dc.publisherPublic Library of Science (PLoS)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleAntifungal activity of well-defined chitooligosaccharide preparations against medically relevant yeastsen_US
dc.typeJournal articleen_US
dc.creator.authorGanan, Monica
dc.creator.authorLorentzen, Silje Benedicte
dc.creator.authorAgger, Jane W.
dc.creator.authorHeyward, Catherine A.
dc.creator.authorBakke, Oddmund
dc.creator.authorKnutsen, Svein Halvor
dc.creator.authorAam, Berit B.
dc.creator.authorEijsink, Vincent G. H.
dc.creator.authorGaustad, Peter
dc.creator.authorSørlie, Morten
cristin.unitcode185,51,12,50
cristin.unitnameSeksjon for fysiologi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1676381
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=PLoS ONE&rft.volume=14&rft.spage=&rft.date=2019
dc.identifier.jtitlePLoS ONE
dc.identifier.volume14
dc.identifier.issue1
dc.identifier.doihttp://dx.doi.org/10.1371/journal.pone.0210208
dc.identifier.urnURN:NBN:no-70731
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn1932-6203
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/67560/2/2019%2BCHOS%2BAntifungal%2BPLOS%2BOne64057.pdf
dc.type.versionPublishedVersion
cristin.articleide0210208
dc.relation.projectNFR/262300
dc.relation.projectNFR/226280


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International